This invention pertains to polypeptide agents that specifically bind to human Interferon-stimulated gene 15 (ISG15). In particular, it describes immunoglobulin single variable domains (ISVDs) that bind to human ISG15, thereby modulating various immune-related activities of the ISG15 protein. The invention further encompasses vectors and nucleic acids encoding these ISVD-based modulators, as well as pharmaceutical compositions containing such ISVD modulators. The ISG15-specific modulator polypeptides, particularly the ISVDs and compositions described herein, may be used for the prevention and/or treatment of immune-related disorders, including bacterial and viral infections, as well as autoimmune diseases.
The invention provides fusion constructs between the diphtheria toxin translocation domain and Fc moieties. These fusion constructs can be used for treatment of solid tumors.
The invention provides fusion constructs between the diphtheria toxin translocation domain, a dimerizing moiety and a cytokine. These fusion constructs can be used for treatment of solid tumors.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/34 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Corynebacterium (G)
The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human and murine CD163 protein and to applications of such polypeptides such as for use as diagnostic agent, for example as an immunotracer. The invention further relates to conjugates, in particular conjugates of polypeptides comprising an immunoglobulin domain binding to human and murine CD163 protein and a further moiety, such as a therapeutic moiety, and to applications of such conjugates.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to a human cortico-striato-nigral circuit on chip comprising: i) a population of human striatal medium spiny neurons (MSNs) MSNs expressing MEIS2, BCL11B and GABAergic lineage markers GAD2 and DLX6-AS1, said MSNs thereby forming a medium spiny neuronal circuit, wherein said medium spiny neuronal circuit comprises at least two subpopulations of MSNs expressing dopaminergic D1- or D2- receptors; ii) a population of nigral dopaminergic neurons expressing FOXA1, LMX1A, EN1 and NR4A2, thereby forming a nigral dopaminergic neuronal circuit; and iii) a population of cortical glutamatergic neurons expressing LHX2 and SLC17A6 and/or SLC17A7, thereby forming cortical circuit; a multi-electrode array (MEA) chip for recording neuronal activity, said neuronal activity resulting at least in part from dopaminergic, GABAergic and/or glutamatergic neurotransmission; wherein said medium spiny neuronal circuit is spatially arranged onto said MEA chip for receiving excitatory and/or modulatory inputs from said cortical circuit iii) and/or said nigral dopaminergic circuit ii); and wherein each one of said populations i)-iii) are differentiated from a human pluripotent stem cell. The present invention further relates to a method for producing said cortico-striato-nigral circuit on chip, and a method of determining the effect of a candidate agent on neuronal activity of the cortico-striato- nigral circuits on chip.
The present invention relates a compound of formula (Ia), (Ib), (Ie), or (If), as defined in the appended claims and description. The present invention also relates to the use of a compound of formula (Ia), (Ib), (Ie), or (If), as defined in the appended claims and description, for inducing resistance against stress in plants and/or parts thereof. The present invention also relates to the use of a compound of formula (I1), as defined in the appended claims and description, for inducing resistance against stress in plants and/or parts thereof. The present invention also relates to a plant seed coated with at least one compound as defined in the appended claims and description, or with a coating composition comprising at least one compound as defined in the appended claims and description. The present invention also relates to an agrochemical composition comprising at least one compound as defined in the appended claims and description, and one or more optional agriculturally acceptable excipient.
A01N 43/10 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with sulfur as the ring hetero atom
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
A01N 43/18 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with sulfur as the ring hetero atom
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
8.
METHOD AND SYSTEM FOR IDENTIFYING BIOMARKERS OF A HEALTH CONDITION
Method and system for identifying biomarkers of a health condition A method for identifying biomarkers of a health condition, comprising: providing a first neuronal circuit with neuronal cells from a first individual organism on a multi-electrode array, applying stimuli to the circuit, obtaining electrophysiological recordings, deriving cell-level and/or circuit-level features from the recordings, associating derived features with presence or absence of the health condition, comparing associated data with reference data, and determining if reference features or derived features are biomarkers for the condition.
Saccharomyces cerevisiaeSaccharomyces cerevisiae strain H147Saccharomyces cerevisiae strain H12Saccharomyces cerevisiae strain H198Saccharomyces cerevisiae strain H200Saccharomyces cerevisiae strain H200, which was deposited on January 13, 2026 at the CNCM under Number I-6292, or a derivative thereof.
The present invention provides novel agrochemicals and formulations thereof and the use of these agrochemical formulations for providing abiotic stress tolerance, such as cold and frost tolerance, in plants.
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
A01N 39/00 - Biocides, pest repellants or attractants, or plant growth regulators containing aryloxy- or arylthio-aliphatic or cycloaliphatic compounds, containing the group or , e.g. phenoxyethylamine, phenylthio-acetonitrile, phenoxyacetone
A01N 43/66 - 1,3,5-Triazines, not hydrogenated and not substituted at the ring nitrogen atoms
C07D 209/48 - Iso-indolesHydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
11.
Microbial compositions for treating joint inflammation
Described herein is a composition of two or more bacterial strains, wherein the composition comprises a bacterial strain of at least two of the following genera: Phascolarctobacterium, Veillonella, Eubacterium, Agathobacter, Lactiplantibacillus, and Anaerostipes. Aspects and embodiments described herein may be used in the treatment of joint inflammation, symptoms thereof, and underlying diseases and conditions.
The present invention relates, in part, to chimeric protein or chimeric protein complex comprising a CD13 targeting moiety and a signaling agent (e.g., without limitation TNF or IFN-γ) and methods of treatment using such compositions.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/1271 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
The invention concerns isolated, monoclonal anti-Tau antibodies and antibody fragments that recognize a phosphorylated amino acid stretch in R3 that overlaps with the hexapeptide PHF6, in particular antibodies and antibody fragments that bind to a conformation-specific epitope in Tau comprising said phosphorylated amino acid stretch and an amino acid stretch in the R1 repeat, for use in the prevention or treatment of a Tauopathy in a subject, as well as use of these antibodies and antibody fragments for in vitro or ex vivo diagnosis of a Tauopathy. The invention further provides nucleic acids encoding these antibodies and antibody fragments, vectors comprising said nucleic acids, and (pharmaceutical) compositions comprising said antibody and antibody fragments, nucleic acids or vectors, as well as their use in the uses and methods of the invention.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention provides binding molecules, particularly antibodies which bind to the IL-12Rβ2. The antibodies are able to bring about the killing of cells expressing IL-12Rβ2 on their surface. The invention further relates to pharmaceutical compositions comprising the binding molecules. The binding molecules and pharmaceutical compositions of the invention may be used in therapy and diagnosis. They may be employed to deplete cells expressing IL-12Rβ2. As IL-12Rβ2 is expressed narrowly, predominately on ‘type 1 immune cells’ such as CD4± Th1, CD8+ Tc1, and ILC1 cells in autoimmune and inflammatory conditions, the binding molecules of the invention may be used to treat and prevent such conditions via such cell depletion.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention provides a computer-implemented method designed to identify genetic alterations which are associated with complex traits in plants. Specifically, the Al model leverages multi-omics embeddings - comprising protein sequence, gene expression, functional data, and other relevant biological information - to enrich predictions of gene-trait relationships. Even more specifically, the Al model comprises a Graph Neural Network (GNN) associating genetic elements (including but not limited to genes and regulatory sequences) to plant features and complex traits. This system continuously refines its understanding of genetic element-complex trait interactions by learning from edits in genetic elements and trait outcomes over iterative cycles. By dynamically improving the model's predictions, the method leads to the development of superior crop varieties that exhibit enhanced complex traits.
The invention relates to the field of genetic engineering and synthetic biology, more particularly to means and methods for facilitating genetic recombination. The application discloses novel Cre recombinase dependent recombination sites that supports a simultaneous cloning and testing approach.
The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses means and methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agent. Said cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the kinetics of said reaction.
The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The invention provides inter alia a method of treating cancer in a subject comprising administering to the subject a first construct comprising an LTBR binding agent and a second construct comprising a topoisomerase inhibitor.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
Institució Catalana De Recerca I Estudis Avançats (Spain)
Inventor
Rousseau, Frederic
Schymkowitz, Joost
Orlando, Gabriele
Serrano Pubul, Luis
Abstract
The present methods and systems generally relate to the biomedical field and relate to subfields of computational biology and bioinformatics. More, specifically the invention provides an artificial intelligence algorithm which can predict the stability of proteins and protein complexes.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The invention relates to a molecular system comprising: (i) at least one dynamic constitutional framework (DCF) comprising a plurality of cores and a plurality of connectors, (ii) a plurality of functional heads, (iii) at least one pillararene and, optionally, (iv) at least one anti-infective agent; wherein each of the anti-infective agents is hosted in one of the pillararenes; wherein the cores, connectors, functional heads, and pillararenes are covalently bound together by reversible bonds; and wherein each of the cores is covalently bound to at least three from the connectors, functional heads and pillararenes. The invention also relates to a pharmaceutical composition or medicament comprising the molecular system. The invention also relates to the molecular system for use in the treatment of an infectious disease such as a bacterial disease, preferably a disease caused by Acinetobacter baumannii bacteria.
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Centre National De Le Recherche Scientifique (France)
Université De Montpellier (France)
Centre Hospitalier Regional Universitaire de Montpellier (France)
Inventor
Tavernier, Jan
Bultinck, Jennyfer
Gerlo, Sarah
Uze, Gilles
Paul, Franciane
Bordat, Yann
Abstract
The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invenon relates to immunogenic pepdes, HLA-immunogenic pepde complexes, and T cell receptors (TCRs) recognizing such HLA-immunogenic pepde complexes. These interacng partners were in parcular obtained starng from TCRs of T cell clones expanding in a cancer paent upon immune checkpoint inhibitor treatment. In parcular, the immunogenic pepdes are derived from the FTHL17 protein. The idenficaon of these clinically relevant molecular interacons provides mulple therapeuc opons and diagnosc tools, including methods for selecng subjects eligible for such therapies.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The invention relates to antigen-binding protein agents specifically binding the hemagglutinin-neuraminidase (HN) protein of human parainfluenza virus 3 (hPIV-3), with cross-reactivity for Sendai Virus (SeV) as well as human parainfluenza virus serotype 1 (hPIV-1) HN, resulting in a cross-neutralizing binding protein to act as a protection agent against parainfluenza infection and/or disease caused by such an infection. More specifically, the invention relates to a family of immunoglobulin single variable domains (ISVDs) capable of broadly blocking HN neuraminidase activity, thereby providing for a novel hPIV-1/-3 cross-neutralizing antiviral protein binding agent. The invention further relates to the use of said antigen-binding proteins in prevention or treatment of acute respiratory tract infections, croup, pneumonia, and exacerbations of chronic obstructive pulmonary disease.
The invention relates to the field of human genetics, more specifically to treatments for a disease or condition associated with an abnormal processing of the Amyloid Precursor Protein (APP), preferably familiar Alzheimer disease (FAD). The invention in particular relates to antisense oligonucleotides (AON's) that can be used for treating such diseases or conditions.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to the field of bacterial protein engineering and protein fibers applicable as metal-binding bionanomaterials. More specifically, the present invention relates to engineered bacterial endospore appendage (Ena) proteins modified to contain metal-binding polypeptide (MBP) inserts providing for stable, flexible and robust protein assemblies with metal-binding activity. In particular, the invention relates to methods for designing Ena-fusion proteins capable of self-assembling into fibers, and for recombinant production of said self-assembling Ena-MBP fusion protein subunits, assemblies and fibers, ensuring a sustainable source of biological material for use in metal mineralization, metal sequestration, and metal-removal applications such as waste water treatment, water softening, or bioremediation.
This disclosure relates to methods of determining the loss of heterozygosity (LOH) status of a tumor and to methods of determining the homologous recombination repair deficiency (HRD) status of a tumor. Such methods further translate into ways of predicting the response of a subject having cancer to treatments or therapies comprising DNA damaging agents and/or agents inhibiting or impairing DNA repair; and into use of such treatments or therapies when the LOH or HRD status of the subject having cancer is positive.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to compounds which are capable to bind the complement component 1, subcomponent q (C1q) and to inhibit its biological activity. More in particular, the present invention discloses the usage of said compounds to prevent or treat fatigue as comorbidity in autoimmune disease.
The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
32.
IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF
Centre National de la Recherche Scientifique (France)
Universite de Montpellier (France)
Inventor
Tavernier, Jan
Van Der Heyden, Jose
Garcin, Genevieve
Uze, Gilles
Bordat, Yann
Abstract
The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to purine synthesis inhibitors for use in the treatment or prevention of kidney cysts and liver cysts in a patient with a kidney disease, wherein the patient did not underwent a kidney transplantation.
The invention relates to the field of bacterial membrane protein structures. More specifically, the invention relates to lipid nanodiscs compartmentalized by SlyB protein oligomers isolated from the outer membrane of Gram-negative bacteria. More specifically, the invention provides for a SlyB nanodisc structure wherein the SlyB-oligomer forms the membrane scaffold protein belt, which is surrounded by outer saccharolipid moieties anchored to the SlyB proteins, and which encloses a lipid bilayer nanodomain containing one or more phospholipid layers, wherein macromolecules such as (outer) membrane protein molecules may be captured and stabilized. More specifically, methods to produce and isolate chemically defined stable SlyB nanodisc particles are disclosed herein. Finally, the invention relates to the use of said SlyB nanodiscs as a self-adjuvanting vehicle, as part of an immunogenic composition, and provides for novel means for use in eliciting an immune response against macromolecules enclosed in said SlyB nanodiscs, or for use in a vaccine composition.
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
35.
MEANS AND METHODS FOR SPRAYING MICRODROPLETS FROM A CHIP
The present invention relates to the field of microfluidic sample preparation, more specifically of biological sample preparation, in particular for spraying microdroplets from a microfluidic chip. In particular, the chip and methods for using the same are applicable in the field of protein sampling, structural biology, even more specifically for structural analysis of proteins by Cryogenic-electron microscopy (Cryo-EM). The invention provides for methods and devices for preparing aqueous protein samples for transmission electron microscopy, typically at millisecond time-resolution using a microfluidics-based integrated device. More specifically, the sampling means and methods of the invention relate to an improved dispensing module integrating distant actuation of the sample for droplet-on-demand microdroplet spraying from the microfluidic chip only requiring very limited sample amounts.
The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present Invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a composition for improving taste, for example for producing and/or enhancing ethanolic taste of a food product, wherein said composition comprises at least piperine and nicotinic acid, and wherein the weight ratio of piperine to nicotinic acid to is from 50:1 to 1:150. The invention further pertains to a food product comprising the composition of the invention and use of said composition for improving the taste of a food product. The invention also relates to a method for producing a beverage, preferably a non-alcoholic, low-alcoholic or alcoholic beverage.
The present invention discloses modified corn plants which have been edited in specific cytokine dehydrogenase genes. These corn plants have a short stature phenotype and have an increased lodging resistance.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventor
Rademakers, Rosa
De Coster, Wouter
Abstract
The invention relates to genetic risk factors that are associated with frontotemporal lobar degeneration (FTLD), in particular with atypical FTLD with ubiquitin inclusions (aFTLD-U). These genetic risk factors are located on the chr15q14 locus and are detectable beyond the brain, thus opening avenues for more precise ante-mortem identification of this type of FTLD patients.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
INSTITUUT VOOR LANDBOUW- EN VISSERIJONDERZOEK (ILVO) (Belgium)
Inventor
Goormachtig, Sofie
Vlaminck, Lena
Willems, Anne
Pannecoucque, Joke
Abstract
BradyrhizobiumBradyrhizobium bacterium having enhanced characteristics, including but not limited to enhanced adaptation to the low and medium root zone temperature for example in North- West Europe.
The present invention relates to a recombinant oleaginous yeast cell having at least one CEX1 gene disruption, comprising chimeric gene constructs, each of said chimeric gene constructs comprising a yeast-expressible promoter and a 3' end region comprising transcription termination and polyadenylation signals functioning in a yeast cell, wherein said chimeric gene constructs allow for overexpression of DGA1, ACC1, MCE2, and ACL genes, said ACL gene being ACL1 and/or ACL2 gene. In a second aspect, the invention relates to a method for producing lipids using said transformed oleaginous yeast cell. The invention further pertains to lipids obtainable by the method, a composition comprising said lipids, a composition comprising transformed oleaginous yeast cell, and a food product obtainable therefrom.
The present invention relates to novel pore monomers which have been elongated to increase the distance between two constrictions, pores formed from the pore monomers, and their uses in analyte detection and characterisation.
The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
44.
INTERLEUKINE-2 MUTEINS WITH ENHANCED SPECIFICITY TOWARDS TREG CELLS AND IMPROVED PRODUCTION CAPACITY
The present invention is aimed at addressing the need for enhanced specificity of IL2 for Treg cell lineage responses while maintaining bioactivity and maintaining or improving production capacity to provide molecules useful as biological tools or therapeutics.
The present invention relates to the field of protein nanofibrils originating from Bacillus sp. provided in a composition as additive to a biologically active substance, in particular to a microbial substance such as a pesticide or plant beneficial agent. More specifically, the present invention relates to a composition comprising an agriculturally bioactive substance and Alpha(helical) Endospore appendage (A-ENA) protein nanofibril materials, more precisely wherein said A-ENA protein nanofibrils are recombinantly produced and exogenously added to said bioactive substance of the composition, thereby functioning as coformulant or additive, and preferably increasing the biological activity of said substance. In particular, the composition of the invention comprises B. thuringiensis spores or cells and self-assembled (engineered or functionalized) A-ENA protein nanofibrils as coformulant, providing for an improved efficacy and/or application potential as pesticide or insecticide. The present invention further relates to a method for controlling plant growth and protection of plants or parts thereof from pest damage, in particular by applying said composition of the invention in an effective amount or formulation, wherein the presence of said A-ENA protein nanofibril coformulant or additive results in increased efficacy and/or virulence of the bioactive substance of said composition, in particular for bioactive substances comprising Bacillus sp. strains.
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC (Australia)
UNIVERSITY OF SOUTH AUSTRALIA (Australia)
Inventor
Liston, Adrian
Dooley, James
Burton, Oliver
Dashwood, Amy
Makuyana, Ntombizodwa
Ghodsinia, Arman
Schymkowitz, Joost
Rousseau, Frederic
Van Der Kant, Rob
Holt, Matthew
Gargett, Tessa
Brown, Michael Paul
Abstract
The present invention relates to modified IL polypeptides for enhanced specificity of IL2, in particular for CD8 T cell lineage responses, while maintaining bioactivity and maintaining or improving production capacity to provide molecules useful as biological tools or therapeutics.
The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
48.
OLIGONUCLEOTIDES FOR MODULATING SYNAPTOGYRIN-3 EXPRESSION
The invention relates to an oligonucleotide comprising a gapmer of formula 5'-F-G-F'-3', where each one of F and F' is a region which independently comprises between 3 and 4 nucleosides, and wherein each one of said F and F' region independently comprises at least one chemically modified nucleoside defining the 5' and 3' end of the F and F' region, and wherein G is a region between 9 and 11 nucleosides for recruiting RNaseH, which oligonucleotide can target regions within the synaptogyrin-3 RNA sequence. In particular, these oligonucleotides are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies.
The invention relates to the application of inhibition of transcription factor 4 (TCF4/ITF2) in the treatment of cancer. This in particular in combination therapy in conjunction with an immunotherapeutic compound (such as for treating cancers poorly responding or refractive to immunotherapy). In particular, inhibition of TCF4/ITF2 is capable of restoring response to immunotherapy such as immune checkpoint inhibitor therapy. Expression levels of TCF4/ITF2 as well as levels of mesenchymal-like cancer cells in a cancer lesion are predictive of future response to immunotherapy early after initiation of the immunotherapy. Further part of the invention are methods of detecting mesenchymal-like cancer cells.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
50.
Glyco-Engineered Yeast for Therapeutic Protein Production
The invention relates to the field of glycoprotein production means and methods. More specifically, the present invention provides for a novel yeast strain with a mutant Och1 gene resulting in modified N-glycosylation properties of said strain. Even more specifically, said mutant Och1 gene comprises a sequence coding for a mutant OCH1 protein in which one amino acid near the catalytic site, corresponding to position 151 of the OCH1 protein of the methylotrophic wild type Pichia pastoris strain, is deleted. More specifically, the use of said mutant yeast strain for recombinant expression of glycoproteins results in more homogenous mammalian-like N-glycan structures on said heterologously produced glycoproteins.
This disclosure relates to an immunoglobulin single variable domain (ISVD)-containing modulator that allosterically binds to a three-dimensional (3D) epitope of a protein complex comprising at least one inhibitory immune receptor and at least one corresponding ligand. The modulator regulates cooperativity within such complexes, thereby affecting the binding affinity and downstream signaling pathways. Specifically, the allosteric modulator of this invention induces positive cooperativity in immunoinhibitory receptor-ligand complexes, thus suppressing immune responses in a spatiotemporally restricted manner. Accordingly, these allosteric modulators are useful as therapeutic agents for inflammatory diseases, such as autoimmune diseases, allergic diseases, or graft-versus-host disease (GVHD). Moreover, this disclosure pertains to methods for identifying, selecting, and producing said allosteric modulators.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This disclosure relates to an immunoglobulin single variable domain (ISVD)-containing modulator that allosterically binds to a three-dimensional (3D) epitope present on the human PD-1•PDL1 (hPD-1•hPD-L1) complex. The modulator regulates cooperativity within this complex, thereby affecting the binding affinity between hPD-1 and hPD-L1 and/or downstream signaling pathways. Specifically, the allosteric modulator of this invention selectively induces positive cooperativity in the hPD-1•hPD-L1 complex, thus suppressing immune responses in a spatiotemporally restricted manner. Accordingly, such allosteric modulators are useful as therapeutic agents for inflammatory diseases, such as autoimmune diseases, allergic diseases, or graft-versus-host disease (GVHD).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Morphoregulator polypeptides that can be used to improve the capacity of the plant cells to regenerate embryogenic plant tissues, plant organs, and whole plants are disclosed. Also disclosed are plant cells comprising the polypeptides and related methods for improving the capacity of the plant cells to regenerate embryogenic plant tissues, plant organs, and whole plants.
A system for monitoring effector cell mediated killing of target cells includes a containment unit with multiple discrete confinement locations, each capable of simultaneously holding at least one effector cell and one target cell. The system also features a lens-free imaging module for capturing images of all cells within the containment unit and a control unit configured to operate the imaging module to capture a sequence of images over time, extract features from these images, and monitor the effector cell mediated killing of the target cells.
The present invention relates to an adenine base editor (ABE), and components thereof. The present invention also relates to a complex comprising an adenine base editor (ABE) and a guide RNA in a functionally associated form. The present invention further relates to a nucleic acid molecule encoding the ABE/guide RNA, an expression construct or a vector comprising a nucleic acid sequence encoding the adenine base editor and/or the nucleic acid sequence encoding the guide RNA. The present invention further relates to a cell comprising an adenine base editor (ABE) and a method of adenine base editing of a target site in a genome of interest in at least one cell of a prokaryotic organism, including bacterial and archaeal organisms, or eukaryotic organism. Besides that, the present invention relates to various methods, kits and uses associated with the ABEs provided.
The invention relates to modulation of the function or expression of Elongation of very long chain fatty acids protein 1 (ELOVL1) and its therapeutic applications. In particular, CD8+ T cells lacking or substantially lacking functional ELOVL1 are envisaged, and adoptive transfer of such CD8+ T cells is useful in the treatment of cancer. Furthermore, ELOVL1 expression in CD8+ T cells is a biomarker for response to cancer therapy including an immune checkpoint inhibitor.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE MONTPELLIER (France)
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER (France)
Inventor
Tavernier, Jan
Bultinck, Jennyfer
Peelman, Frank
Uze, Gilles
Abstract
The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
60.
DE NOVO DESIGN OF ANTIBODIES TARGETING A SPECIFIC EPITOPE
FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (CRG) (Spain)
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) (Spain)
Inventor
Rousseau, Frederic
Schymkowitz, Joost
Van Der Kant, Rob
Zhang, Zhongyao
Dewilde, Maarten
Serrano Pubul, Luis
Delgado Blanco, Francisco Javier
Cianferoni, Damiano
Abstract
The present invention relates to methods and systems which relate to the biomedical field and relate to subfields of computational biology and bioinformatics. More, specifically the invention provides a computer-implemented algorithm which can produce a panel of antibodies directed to an epitope of choice.
The current invention relates to an improved microfluidic device for protein/protein complex purification, as well as an associated methodology and system.
The current invention relates to an improved microfluidic device for protein/protein complex purification, as well as an associated methodology and system.
In particular it relates to systems and methods for electron microscopy, preferably cryogenic electron microscopy (cryo-EM), on protein samples, comprising: a. at least one microfluidic chip with inlet and outlet and purification device; b. at least one illumination means and detection means for, preferably fluorescence, measurements on the microfluidic chip; c. a pumping system adapted for operable connection to the microfluidic chip, and configured for controlling flow in the operably connected microfluidic chip; d. a microscopy grid, preferably a cryogenic electron microscopy (cryo-EM) grid, for holding fluid samples; e. preferably a cryogenic container, for a cryogenic coolant; f. preferably a transport system for moving the cryo-EM grid between a position for receiving a fluid sample from the microfluidic chip and the cryogenic container; g. a control system, preferably a processor, which receives information on the measurements from the detection means, configured for controlling the pumping system at least based on said information, and further configured for controlling the illumination and detection means and preferably also for controlling the transport system.
Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-COV-2, including SARS-COV-2 variants, and SARS-COV. 1. The binding agents, in particular the antibodies and antibody fragments, bind to heptad repeat 2 (HR2) domain of spike protein of the Sarbecovirus, more particularly to a quaternary epitope located within 2 adjacent HR2 domains. Also disclosed are methods using these binding agents and uses thereof.
The invention relates to the field of cell surface display and selection of Fc-containing molecules such as antibodies or alike, and/or selection of Fc-containing molecule-expressing clones. In particular, the invention relates to a method for displaying Fc-containing proteins on a cell, in particular wherein said method further relates to selection of yeast clones recombinantly expressing Fc-containing proteins. The invention further relates to a capturing or binding agent comprising a Fc-binding protein and an oligomannose binding protein, wherein the oligomannose binding protein specifically binds oligomannose or mannan on the outside of a cell, in particular a yeast cell. In particular, the invention discloses a binding agent comprising a bivalent ZZ domain or an antigen-binding domain specifically binding to Fc-tails, and comprising a lectin domain, wherein the lectin preferably binds yeast mannans. The invention further relates to a method for cell surface display of Fc-containing proteins wherein the capturing agent is applied to a population of cells to connect the cell surface via oligomannose-binding to the secreted Fc-containing proteins recombinantly expressed by said cell. In particular, the invention relates to said method further used to isolate the cells with the highest number of secreted Fc- containing proteins by cell sorting of the displayed cells.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C07K 14/42 - Lectins, e.g. concanavalin, phytohaemagglutinin
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
The present invention relates to a method and composition for prevention and treatment of infections in a subject, in particular, with intracellular bacteria. The invention provides an optimized intracellular delivery of an active agent, in particular, a nucleic acid, using a nanoparticle formulation including an iNKT cell agonist.
Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.
This application relates to polypeptide agents and compositions specifically binding human beta-glucocerebrosidase (GCase, GBA1). Particularly, immunoglobulin single variable domains (ISVDs) are described which allosterically bind human GCase, thereby positively modulating GCase in its stability and/or catalytic activity. The invention relates further to vectors and nucleic acids encoding such ISVD-based modulators. Also encompassed are compositions, in particular pharmaceutical compositions, containing such ISVD modulators. The GCase-specific allosteric modulators, specifically the ISVDs and compositions described herein, may be used for prevention and/or treatment of GCase-related diseases, including Gaucher disease (GD) and Parkinson's disease (PD).
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations; Medicinal healthcare preparations; drugs for medical purposes; Diagnostic preparations for medical purposes; Biochemical preparations for medical use; Biotechnological preparations for medical use. Scientific services and design relating thereto, not in the field of science and technology relating to the supply, treatment and disposal of water, energy and waste, in particular for utilities, industrial and commercial enterprises; Technological services and design relating thereto, not in the field of science and technology relating to the supply, treatment and disposal of water, energy and waste, in particular for utilities, industrial and commercial enterprises; Scientific and technological design, not in the field of science and technology relating to the supply, treatment and disposal of water, energy and waste, in particular for utilities, industrial and commercial enterprises; Advisory services relating to technological research, not in the field of science and technology relating to the supply, treatment and disposal of water, energy and waste, in particular for utilities, industrial and commercial enterprises; Consultancy services relating to technological research, not in the field of science and technology relating to the supply, treatment and disposal of water, energy and waste, in particular for utilities, industrial and commercial enterprises; Research relating to medicines; Medical research services.
The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor, more specifically agents comprising an immunoglobulin single variable domain (ISVD) which allow internalisation upon binding to the extracellular N-terminal domains 1, 2 and/or 3 in monovalent format. More specifically said ISVD provides for means and methods for lysosomal targeting, especially when fused to further proteins such as enzymes relevant for treatment of diseases caused by a lysosomal storage phenotype or lysosomal storage diseases. Finally the binding agents of the invention provide for use in therapeutic treatments, such as in Enzyme-replacement therapy, more specifically, when fused to human acid α-glucosidase (hGAA) or human cathepsin D proteases for treatment of Pompe disease or sporadic inclusion body myositis or neuronal ceroid lipofuscinosis 10 (CLN10), respectively.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Germany)
Inventor
Goossens, Alain
Lacchini, Elia
Schillberg, Stefan
Schinkel, Helga
Qu, Tongtong
Abstract
This invention provides methods for the production of glycosylated triterpenoids which function as endosomal escape enhancers. Specifically, the invention provides UDP glycosyltransferases (UGTs) useful for the biosynthesis of these glycosylated triterpenoid saponins. The invention also provides in vitro systems and plant extracts comprising UDP glycosyltransferases and sapofectosid precursors.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
71.
MEANS AND METHODS FOR THE INDUCTION OF PROTEIN DEGRADATION
The invention provides means and methods to identify amino acids in target proteins which are crucial weak spots for the native protein stability. Such regions are useful for screening of compounds interacting with such amino acid regions. Compounds identified with this technology can induce the misfolding and subsequent cellular degradation of a target protein.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
The present invention relates to a combination comprising an oncolytic virus and an LTBR agonist. The LTBR agonist may be administered separately or may be encoded by the oncolytic virus. Such a combination is particularly useful for use in the treatment of a cancer.
The present invention provides chimeric genes and constructs which can be used to alter the lignin composition of woody plants and increase the saccharification and pulping efficiency of said plants. Particularly the lignin composition is modified by the incorporation of scopoletin.
The present invention relates to a transmembrane beta barrel polypeptide. In another aspect, the invention concerns a nanopore comprising a lumen and a wall, wherein said wall comprises the transmembrane beta barrel polypeptide. In a further aspect, the invention concerns a pharmaceutical composition comprising the transmembrane beta barrel polypeptide and/or the nanopore. In further independent aspects the present invention pertains to a computer-implemented method for obtaining the transmembrane beta barrel polypeptide and method for producing the transmembrane beta barrel polypeptide in a host cell.
FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Germany)
THE MAGNA GRAECIA UNIVERSITY OF CATANZARO (Italy)
UNIVERSITEIT ANTWERPEN (Belgium)
UNIVERSITY OF NAPLES FEDERICO II (Italy)
VIB VZW (Belgium)
Inventor
Gribbon, Phil
Keminer, Oliver
Leo, Antonio
Citraro, Rita
De Sarro, Giovanbattista
Weckhuysen, Sarah
Taglialatela, Maurizio
Miceli, Francesco
Carotenuto, Lidia
Abstract
The invention is based on the repurposing of a clinically safe compound as a potassium channel activator for treating hyperexcitability related disorders. The invention also relates to a pharmaceutical composition comprising a compound of the present invention, as well as a method of treating hyperexcitability related disorders using the disclosed compounds or a pharmaceutical composition of the invention.
The present invention relates to the field of the human gut microbiome, more particularly to its effect on health and disease. Provided herein are means and methods of classifying the gut microbiome based on qPCR data. The invention also provides methods to diagnose and treat or reduce the severity of gut flora dysbiosis as well as of gastro-intestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
The invention relates to methods of processing of Doppler signals or echoes obtained from insonation of a tissue, in particular a cerebral tissue. The methods in particular enable determination of a hemodynamic parameter independent of the insonated tissue region and enable comparison between different individuals in an operator-independent manner.
The invention relates to antigen-binding polypeptides specifically binding neuraminidase and/or haemagglutinin protein from Influenza B virus resulting in broadly neutralizing IBV antigen-binding polypeptides or antibodies. More specifically the invention relates to immunoglobulin single variable domains specifically binding NA or HA, which upon fusion to bispecific antigen-binding proteins provide for a broader and improved neutralization capacity as compared to a combination of IBV NA- and HA- targeting ISVDs or antibodies. The invention further relates to the use of said antigen-binding proteins for medical purposes, more specifically in prophylactic or therapeutic treatment of a subject, even more specifically to prevent or treat IBV infections.
The present invention relates to the field of the human gut microbiome, more particularly to its effect on health and disease. Provided herein are means and methods of classifying the gut microbiome based on qPCR data. The invention also provides methods to diagnose and treat or reduce the severity of gut flora dysbiosis as well as of gastro-intestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
80.
OPTIMIZED SARBECOVIRUS SPIKE S2 SUBUNIT BINDERS AND COMPOSITIONS COMPRISING THE SAME
This invention relates to Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-CoV-2, including SARS-CoV-2 variants, and SARS-CoV- 1, and affinity matured variants thereof. The binding agents, in particular the antibodies and antibody fragments, have one or more favourable antibody development characteristics. The invention also relates to methods using these binding agents and uses thereof.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
The Regents of the University of Michigan (USA)
Inventor
Steyaert, Jan
Pardon, Els
Laeremans, Toon
Kobilka, Brian
Rasmussen, Soren G.F.
Granier, Sebastien
Sunahara, Roger K.
Abstract
The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present disclosure can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
83.
INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 1 AS MEANS FOR TREATING CANCER
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
84.
HEMATOPOIETIC PROSTAGLANDIN SYNTHASE (HPGDS) INHIBITION FOR TREATING CANCER
The disclosure relates to the medical use of inhibitors of expression or function of the hematopoietic prostaglandin synthase (HPGDS) in the treatment of cancer in general or more in particular in the treatment of cancer in which HPGDS is predominantly expressed by tumor-associated macrophages in the tumor micro-environment. Inhibition of HPGDS as enhancer of immune checkpoint inhibitor therapy is also disclosed, as are (companion) diagnostic methods. The disclosure further relates to isolated macrophages in which HPGDS expression or function is inhibited, such as for medical use.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The disclosure relates to the medical use of inhibitors of expression or function of the prostaglandin D2 receptor 2 in the treatment of cancer in general or more in particular in the treatment of cancer in which HPGDS is predominantly expressed by tumor-associated macrophages in the tumor micro-environment. The disclosure further relates to isolated macrophages in which prostaglandin D2 receptor 2 expression or function is inhibited, such as for medical use.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
86.
INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 2 AS MEANS FOR TREATING CANCER
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
87.
INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 1 AS MEANS FOR TREATING CANCER
The disclosure relates to the medical use of inhibitors of expression or function of the prostaglandin D2 receptor 1 in the treatment of cancer in general or more in particular in the treatment of cancer in which HPGDS is predominantly expressed by tumor-associated macrophages in the tumor micro-environment. The disclosure further relates to isolated immune cells in which prostaglandin D2 receptor 1 expression or function is inhibited, such as for medical use.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
88.
SBLE MUTANTS WITH ALTERED ACTIVITY AND SBLE HOMOLOGUES
The invention relates to the field of analyzing parameters in the perfusate of an organ under ex situ organ perfusion conditions. In particular the identified parameters include 1 or more of arginine, glutamate, glucose, glutamine, lactate, alanine, leucine and isoleucine; and are capable of accurately determining the extent of damage present in the perfused organ. Several applications of the assessment of these identified parameters are also part of the invention.
This disclosure relates to methods of determining the response of a tumor to DNA-damaging agents or to agents inhibiting or impairing DNA repair (such as inhibitors of the poly ADP ribose polymerase or to platinum-based agents). In particular such methods include computer-assisted classification of a test genomic DNA sample based on BRCA gene mutation status, a BRCA domain mutation feature, and a loss- of-heterozygosity feature, wherein the classifier has been trained on set of the corresponding statuses and features of reference genomic DNA samples of subjects known to respond to DNA-damaging agents or to agents inhibiting or impairing DNA repair.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
91.
METHOD OF DETECTING LOSS OF HETEROZYGOSITY STATUS OF A TUMOR
This disclosure relates to methods of detecting the loss of heterozygosity (LOH) status of a tumor and to methods of detecting the homologous recombination repair deficiency (HRD) status of a tumor. Such methods further translate into ways of predicting the response of a subject having cancer to treatments or therapies comprising DNA damaging agents and/or agents inhibiting or impairing DNA repair; and into use of such treatments or therapies when the LOH or HRD status of the subject having cancer is positive.
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 213/16 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
94.
Improved Probiotic Potency of the Yeast Saccharomyces Boulardii
The present invention relates to the field of probiotics, more particularly to the probiotic yeast Saccharomyces boulardii. The present invention provides genetic engineering approaches such as the use of gene deletions and the use of chimeric gene constructs to develop yeast strains with enhanced production of acetic acid. In addition, the invention also relates to the use of such yeast strains for the production of dietary supplements or pharmaceutical compositions to improve gastrointestinal comfort.
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
96.
MULTISPECIFIC ANTIBODIES FOR NEUROLOGICAL DISORDERS
The invention relates to multispecific polypeptides comprising a first protein for the prevention, treatment or detection of a neurological disorder in the central nervous system, a second protein binding specifically to a protein expressed on the blood brain barrier, wherein the protein expressed on the brain blood barrier mediates enhanced uptake of compounds over the BBB, and a third protein binding specifically to a protein in the CNS.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present invention relates to the field of microbial self-assembling protein fibrils as novel bionanomaterials. More specifically, the present invention relates to protein nanofibril materials comprising Bacillus endospore appendage (ENA) proteins, which are spontaneously folding helix hairpin subunits assembling into alpha-helical multimeric (A-ENA) fibrils with a hydrophobic core and covalently connected by one or more isopeptidic bonds, providing for a nanofibril of high stability and tensile strength. The invention further relates to said protein nanofibrils which are engineered or modified to provide for functionalized bionanomaterials. In particular, the invention relates to methods for recombinant production of said self-assembling protein nanofibrils, and their use in modifying bacterial endospores and endospore activity or pathogenicity.
The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the reaction kinetics.
The invention relates to the field of CAR-T cell immunotherapy, more specifically the invention relates to production and uses of glyco-engineered CAR-T cells for the improvement of immunotherapy compositions for treatment of cancer, more specifically of solid tumors. The invention specifically relates to human CAR-T cells with a mutated MGAT5 gene, as to provide for surface glycan structures devoid of tetra-antennary N-glycans, which results in a sustained memory when applied in immunotherapy, to cure cancer, reduce (recurrent) tumor growth and tumor burden, as well as to prevent relapse. The invention further relates to methods for manufacturing of those CAR-T cells, wherein addition of low amounts of DMSO during activation and expansion ex vivo skews T cell populations to a more predominant memory phenotype, thereby providing for improved glycol-engineered CAR-T cell compositions for adoptive T cell transfer.
